ELCC 2019: First-Line Treatment With Osimertinib in Advanced EGFR -Mutant NSCLC
Posted: Friday, April 26, 2019
The final results from two phase I expansion cohorts confirmed the efficacy of osimertinib in the first-line treatment of EGFR mutation–positive advanced non–small cell lung cancer (NSCLC). Consistent with previous reports, osimertinib prolonged progression-free survival in patients who received the third-generation tyrosine kinase inhibitor (TKI). James Chih-Hsin Yang, MD, PhD, of the Graduate Institute of Oncology at the National Taiwan University in Taipei City, and colleagues presented the final update of the AURA trial at the 2019 European Lung Cancer Congress (ELCC) in Geneva (Abstract 122P).
As a central nervous system–active EGFR TKI, osimertinib selectively inhibits both EGFR TKI–sensitizing and EGFR T790M–resistance mutations. In this study, 60 treatment-naive patients with locally advanced or metastatic mutation-positive NSCLC received osimertinib at either 80 mg (n = 30) or 160 mg (n = 30) daily.
At the data cutoff, 11 patients remained on osimertinib. The median duration of response in the 80-mg and 160-mg cohorts was 19.3 months and 16.7 months, respectively; at 78% data maturity, the median progression-free survival was 22.1 months and 19.3 months, respectively.
Overall, patients receiving the 80-mg dose reported better tolerability; dose reductions occurred in 27% and 60% of patients who received 80 mg and 160 mg, respectively. All patients in both cohorts experienced at least one adverse event of any grade. Diarrhea (3%) was the most commonly reported grade ≥ 3 adverse event among patients receiving osimertinib at 80 mg. In the 160-mg cohort, the most common grade ≥ 3 adverse events included diarrhea (7%), stomatitis (3%), and paronychia (10%).
Disclosure: The study authors’ disclosure information may be found at cslide.ctimeetingtech.com.
